NRx Pharmaceuticals (NRXPW) Stock Analysis

What NRx Pharmaceuticals does

NRx Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development of novel therapies for central nervous system ailments and life-threatening lung conditions. Its portfolio includes ZYESAMI, an investigational medicine that has progressed through Phase IIb/III clinical trials for severe respiratory distress linked to COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, orally administered treatments engineered to address bipolar depression in individuals exhibiting both acute and sub-acute suicidal ideation and actions. This Delaware-based company, located in Wilmington, was established in 2015.

Key metrics

ETFs linked to NRXPW

Broad-market and Healthcare sector ETFs an investor holding NRx Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how NRXPW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for NRx Pharmaceuticals?

NRx Pharmaceuticals trades under the ticker NRXPW on NASDAQ.

Which exchange is NRXPW listed on?

NRXPW is listed on NASDAQ.

What sector does NRx Pharmaceuticals operate in?

NRx Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze NRXPW in a portfolio?

PortView shows NRXPW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.